Galapagos NV (Galapagos NV) Other Gross PPE : $135.9 Mil (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Galapagos NV Other Gross PPE?

Galapagos NV's Other Gross PPE for the quarter that ended in Mar. 2024 was $135.9 Mil.

Galapagos NV's quarterly Other Gross PPE declined from Sep. 2023 ($146.0 Mil) to Dec. 2023 ($32.7 Mil) but then increased from Dec. 2023 ($32.7 Mil) to Mar. 2024 ($135.9 Mil).

Galapagos NV's annual Other Gross PPE declined from Dec. 2021 ($110.5 Mil) to Dec. 2022 ($49.2 Mil) and declined from Dec. 2022 ($49.2 Mil) to Dec. 2023 ($32.7 Mil).

Galapagos NV Other Gross PPE Historical Data

The historical data trend for Galapagos NV's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV Other Gross PPE Chart

Galapagos NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Gross PPE

Get a 7-Day Free Trial

50.25

93.61

110.49

49.18

32.65

Galapagos NV Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Gross PPE	Get a 7-Day Free Trial															144.42	145.97	146.00	32.65	135.93

Galapagos NV Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

Galapagos NV (Galapagos NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (NAS:GLPG) » Definitions » Other Gross PPE

Comparable Companies

Traded in Other Exchanges

GLPG:Netherlands GLPG:Mexico 0JXZ:UK GXE:Germany G1LP34:Brazil GLPG:Austria

Address

Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800

Website

https://www.glpg.com

Galapagos NV is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.